GAM
ALNY icon

Groupama Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Groupama Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
34,252
-2,515
-7% -$759K 0.13% 83
2026
Q1 		$12.2M Buy
36,767
+889
+2% +$303K 0.18% 77
2025
Q4 		$14.3M Buy
35,878
+3,796
+12% +$1.68M 0.21% 72
2025
Q3 		$18.6M Sell
32,082
-16,303
-34% -$6.64M 0.27% 64
2025
Q2 		$17.6M Buy
48,385
+8,246
+21% +$2.28M 0.29% 64
2025
Q1 		$12.5M Buy
40,139
+11,689
+41% +$3M 0.25% 67
2024
Q4 		$8.32M Buy
28,450
+7,065
+33% +$1.86M 0.17% 83
2024
Q3 		$6.13M Sell
21,385
-2,849
-12% -$742K 0.16% 96
2024
Q2 		$5.89M Buy
24,234
+21,978
+974% +$3.47M 0.08% 120
2024
Q1 		$3.25M Sell
2,256
-15,061
-87% -$2.51M 0.06% 173
2023
Q4 		$3.32M Buy
+17,317
New +$2.95M 0.09% 146

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Groupama Asset Management's ALNY Position: Q2 2026 in Review

Groupama Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.8% in Q2 2026, selling an estimated $759K and leaving 34,252 shares worth $10.3M. The position accounts for 0.13% of the portfolio, ranked #83.

Groupama Asset Management first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $18.6M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Groupama Asset Management held 34,252 shares of Alnylam Pharmaceuticals worth $10.3M as of Q2 2026.
  • Groupama Asset Management sold 2,515 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $759K.
  • Alnylam Pharmaceuticals made up 0.13% of Groupama Asset Management's portfolio in Q2 2026, its #83 holding.
  • Groupama Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Groupama Asset Management's Alnylam Pharmaceuticals position peaked at $18.6M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.